Pacific Biosciences Introduces New Chemistry With Longer Read Lengths to Detect Novel Features in DNA Sequence and Advance Genome Studies of Large Organisms
Thursday, October 3, 2013
provide extremely long sequencing reads.
A complete genome sequence is an extremely valuable tool in many types of scientific research, yet most organisms do not have their complete genome assembled — including humans. Instead, complex genomes are partially completed with difficult repetitive sections and longer structural variants excluded from the assembly, resulting in highly fragmented, incomplete genomes. To sequence the complete genome of an organism, very long sequencing reads are required to span these regions, which can be critical in understanding gene function. The very long sequence reads provided by the PacBio RS II Single Molecule, Real-time (SMRT®) sequencing system provide researchers the opportunity to fill gaps or reduce the number of fragments in assemblies of moderate and large genomes.
“With the P5-C3 release, we saw another step change in the evolution of PacBio data,” said Dr.
“Following our steady stream of system and chemistry improvements during 2013, including our v3 SMRT Cells, the PacBio RS II launch and the highly accurate polymerase P4, this release is our next generation chemistry upon which future developments and read length improvements will be built,” said
The latest release also includes 20,000-base size-selected library protocols optimized for use with the Sage Science BluePippin™ DNA size selection system, along with an upgraded version of SMRT Analysis (available at http://pacbiodevnet.com/), which introduces an update to the popular HGAP assembler. The new HGAP 2 assembler significantly decreases the time required to perform de novo genome assembly. These HGAP performance enhancements also extend the range of genome sizes that can be assembled. Additional software features include diploid-aware SNP detection as well as haplotype phasing of amplicons, which provides users the opportunity to utilize the platform for applications such as HLA analysis. The new reagents
are available in addition to the previously released P4-C2 chemistry, which is still recommended for PacBio-only de novo assembly, minor-variant detection, targeted sequencing, and cDNA applications.
Researchers attending the 2013
More information about the PacBio RS II and the latest product enhancements is available at: www.pacb.com.
About Pacific Biosciences
Forward Looking Statements
This press release contains forward-looking statements relating to the current or future performance of products and product enhancements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and that could materially affect actual results. Factors that could materially affect actual results can be found in the Company’s filings with the Securities and Exchange Commission, including the most recently filed Quarterly Report on Form 10-Q, and include those listed under the caption “Risk Factors.” The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
CONTACT: For Pacific Biosciences: Media:
Maurissa MessierFor Pacific Biosciences 760.539.7417 email@example.com Investors: Trevin RardPacific Biosciences 650.521.8450 firstname.lastname@example.org
News Provided by Acquire Media